Supernus Pharmaceuticals | SUPN - Debt


Supernus Pharmaceuticals reported $42.21M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Abbott USD 12.94B 496M Sep/2025
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 6.36M 247K Sep/2025
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 372.19M 4.53M Dec/2025
Perrigo USD 3.64B 7.2M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Supernus Pharmaceuticals USD 42.21M 10.44M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025